| 1 |
33960741 | Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. | 2021 Jun |
1 |
| 2 |
33376301 | Brexpiprazole for the Treatment of Schizophrenia in Adults: An Overview of Its Clinical Efficacy and Safety and a Psychiatrist's Perspective. | 2020 |
1 |
| 3 |
31406978 | Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review. | 2019 Oct 1 |
1 |
| 4 |
31487433 | Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5-HT2A receptors in rats. | 2019 Dec |
1 |
| 5 |
31735758 | [Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI® Tablets 1 mg, 2 mg)]. | 2019 |
1 |
| 6 |
26831200 | Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. | 2016 |
1 |
| 7 |
26250067 | Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? | 2015 Sep |
1 |
| 8 |
26261843 | Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder. | 2015 Jul |
2 |